HHS Reserves COVID-19 Vaccine Manufacturing Capacity at Fujifilm’s Texas Facility
HHS’ Biomedical Advanced Research and Development Authority (BARDA) has issued a $285 million contract to reserve vaccine manufacturing capacity at Fujifilm’s facility in College Station, Texas.
The contract with the Texas A&M System’s Center for Innovation in Advanced Development and Manufacturing (CIADM) will reserve part of the facility’s vaccine output through December 2021. The CIADM is a public-private partnership between BARDA and Texas A&M with manufacturing subcontracted to FUJIFILM Diosynth Biotechnologies.
The contract, which is part of the U.S. government’s Operation Warp Speed, will accelerate a capacity expansion at the facility for completion by fall 2020.